INCY - Incyte Corporation
After hours:
| Previous close | 61.51 |
| Open | 61.50 |
| Bid | 62.54 x 800 |
| Ask | 62.40 x 800 |
| Day's range | 61.42 - 62.60 |
| 52-week range | 60.71 - 86.29 |
| Volume | |
| Avg. volume | 1,667,793 |
| Market cap | 13.952B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 43.13 |
| EPS (TTM) | 1.45 |
| Earnings date | 31 Jul 2023 - 04 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 82.24 |
Business WireData from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
WILMINGTON, Del., May 25, 2023--Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
Business WireIncyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
WILMINGTON, Del., May 08, 2023--Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
- Investing.com
4 big analyst cuts: PacWest slashed, stock crashes on sale talks | Pro Recap
The news comes after Bloomberg reported that the bank has been weighing a range of strategic options amid concerns about its financial health.
ZacksIncyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
ZacksIncyte (INCY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksIncyte (INCY) Q1 Earnings and Revenues Miss Estimates
Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireIncyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del., May 02, 2023--Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Business WireIncyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
WILMINGTON, Del., May 01, 2023--SCRATCH-AD Trial Demonstrates Substantial, Rapid Itch Reduction in Mild-Moderate Atopic Dermatitis Patients Treated with Opzelura (ruxolitinib) Cream
ZacksThe Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
ZacksWill Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
- Zacks
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksBiotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
ZacksIncyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksIncyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Business WireIncyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
WILMINGTON, Del., April 20, 2023--European Commission Approves Opzelura (ruxolitinib) Cream asTreatment for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
Business WireIncyte to Present at Upcoming Investor Conferences
WILMINGTON, Del., April 18, 2023--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May:
Business WireMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
BOSTON & WILMINGTON, Del., April 16, 2023--5-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
Business WireIncyte to Report First Quarter Financial Results
WILMINGTON, Del., April 11, 2023--Incyte to Report First Quarter Financial Results
ZacksIncyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.
ZacksBiotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
ZacksIncyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
Business WireIncyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
WILMINGTON, Del. & TOKYO, March 27, 2023--Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
ZacksIncyte (INCY) Gets CRL for Jakafi Extended-Release Tablets
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
Business WireIncyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
WILMINGTON, Del., March 24, 2023--Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets